CRISPR effector system based diagnostics

Patent metadata

Field	Value
Publication number	US-12037639-B2
Application number	US-201916285128-A
Country	US
Kind code	B2
Filing date	Feb 25, 2019
Priority date	Dec 9, 2016
Publication date	Jul 16, 2024
Grant date	Jul 16, 2024

Abstract

The embodiments disclosed herein utilized RNA targeting effectors to provide a robust CRISPR-based diagnostic with attomolar sensitivity. Embodiments disclosed herein can detect broth DNA and RNA with comparable levels of sensitivity and can differentiate targets from non-targets based on single base pair differences. Moreover, the embodiments disclosed herein can be prepared in freeze-dried format for convenient distribution and point-of-care (POC) applications. Such embodiments are useful in multiple scenarios in human health including, for example, viral detection, bacterial strain typing, sensitive genotyping, and detection of disease-associated cell free DNA.

First claim

What is claimed is:

1. A composition consisting of:
a Cas13 having collateral cleavage activity;
at least one guide polynucleotide comprising a guide sequence that hybridizes with a target RNA sequence capable of activating a Cas13, and designed to form a complex with the Cas13;
an RNA polymerase and a primer capable of binding to a target DNA sequence and comprising an RNA polymerase promoter, capable of transcribing the target RNA sequence from the target DNA sequence; and
an RNA-based masking construct that comprises a non-target RNA oligonucleotide sequence to which are attached a fluorophore and a quencher of the fluorophore, the construct being designed and arranged so that the fluorophore and quencher are in sufficient proximity for quenching to occur, and that is susceptible to cleavage by the Cas13 collateral cleavage activity so that the quenching is relieved and the fluorophore detectably fluoresces.

2. The composition of claim 1 , wherein the target RNA sequence and/or target DNA sequence is an amplicon.

3. The composition of claim 1 , wherein the Cas13 comprises one or more HEPN domains.

4. The composition of claim 3 , wherein the one or more HEPN domains comprise a RxxxxH motif sequence.

5. The composition of claim 4 , wherein the RxxxxH motif comprises a R[N/H/K]X1X2X3H sequence, wherein X1 is R, S, D, E, Q, N, G, or Y, and X2 is independently I, S, T, V, or L, and X3 is independently L, F, N, Y, V, I, S, D, E, or A.

6. The composition of claim 1 , wherein the Cas13 is a Cas13a.

7. The composition of claim 1 , wherein the Cas13 is a Cas13b, a Cas13c, or a Cas13d.

8. The composition of claim 1 , further comprising reagents for amplifying the target RNA sequence and/or the target DNA sequence.

9. The composition of claim 8 , wherein the reagents for amplifying the target RNA sequence and/or the target DNA sequence are isothermal amplification reagents, optionally wherein the isothermal amplification reagents are nucleic-acid sequence-based amplification, recombinase polymerase amplification, loop-mediated isothermal amplification, strand displacement amplification, helicase-dependent amplification (HDA), or nicking enzyme amplification.

10. A kit consisting of:
an RNA polymerase and a primer capable of binding to a target DNA sequence and comprising an RNA polymerase promoter, capable of transcribing a target RNA sequence capable of activating a Cas13 from the target DNA sequence; and
a Cas13 having collateral cleavage activity; and
an RNA-based masking construct comprising a non-target nucleic acid sequence and that is susceptible to cleavage by the Cas 13 collateral cleavage activity.

11. The kit of claim 10 , further comprising at least one guide polynucleotide comprising a guide sequence that hybridizes with the target RNA sequence and designed to form a complex with the Cas13.

12. The kit of claim 10 , wherein the Cas13 comprises one or more HEPN domains.

13. The kit of claim 12 , wherein the HEPN domain comprise a RxxxxH motif sequence.

14. The kit of claim 13 , wherein the RxxxxH motif comprises a R[N/H/K]X1X2X3H sequence, wherein X1 is R, S, D, E, Q, N, G, or Y, and X2 is independently I, S, T, V, or L, and X3 is independently L, F, N, Y, V, I, S, D, E, or A.

15. The kit of claim 10 , wherein the Cas13 is a Cas13a.

16. The kit of claim 10 , wherein the Cas13 is a Cas 13b, a Cas13c, or a Cas13d enzyme.

17. The kit of claim 10 , further comprising reagents for amplifying the target RNA sequence and/or the target DNA sequence, optionally wherein the reagents for amplifying the target RNA sequence and/or the target DNA sequence are isothermal amplification reagents.

18. The kit of claim 17 , wherein the isothermal amplification reagents are nucleic-acid sequence-based amplification, recombinase polymerase amplification, loop-mediated isothermal amplification, strand displacement amplification, helicase-dependent amplification (HDA), or nicking enzyme amplification.

Assignees

• Broad Inst Inc
• Massachusetts Inst Technology
• Harvard College

Inventors

• Abudayyeh Omar
• Collins James Joseph
• Gootenberg Jonathan
• Zhang Feng
• Lander Eric S

Classifications

• C12Q1/6888

  for detection or identification of organisms · CPC title

• C12Q1/70

  involving virus or bacteriophage {(immunoassay for viruses G01N33/56983)} · CPC title

• C12Q2600/156

  Polymorphic or mutational markers · CPC title

• C12Q1/6886

  for cancer (immunoassay for cancer G01N33/575) · CPC title

• C12Q1/6883

  for diseases caused by alterations of genetic material · CPC title